



CAPT ACTP

**The Canadian Association for Population Therapeutics/
Association Canadienne pour la Thérapeutiques des Populations**

Presents:

**“Managing risk to improve health
outcomes: how to move population health
forward in an era of uncertainty”**

PROGRAM

**October 26th – 27th, 2020
Virtual Conference**

Registration

<https://www.capt-actp.ca/conference/>

CAPT-ACTP MISSION & VISION

The CAPT-ACTP Mission is to advance epidemiologic research of therapeutic and other health interventions in Canada by:

- Bringing together diverse perspectives in a neutral forum
- Facilitating open exchange of ideas and collaboration
- Influencing policy and practice

The CAPT-ACTP Vision is to become the recognized Canadian leader for linking population-based therapeutic research, policy and practice that may lead to improved health outcomes.

www.capt-actp.ca

CAPT-ACTP 2019 Conference Committees

Executive:

President – Luca Pisterzi
President Elect – Shazia Hassan
Past President – Lois Mitchell
Treasurer – Shazia Hassan

Finance Committee:

Treasurer – Shazia Hassan
Executive Director – Marjorie Morrison
Administrator – Peggy Kee

Local Organizing Committee:

Members – Peggy Kee

Marketing, Membership & Student Committee:

Chair: Luca Pisterzi
Student Rep: Shanna Trenaman
Members – Marjorie Morrison – Executive Director
Elena Lungu
Mary de Vera
Jon Feairs
Paul Henricks
Vidhi Thakkar
Peggy Kee

Partnership Committee:

Chair –Lois Mitchell
Members – Graeme Ball
Shazia Hassan (bridge to SPC)
Adam Haynes
Paul Henricks
Elena Lungu
Dan Palfrey
Luca Pisterzi
Peggy Kee
Mina Tadrous

Scientific Committee:

Co-Chairs – Shazia Hassan
Members -- Graeme Ball
Mary de Vera
Jon Feairs
Adam Haynes
Lois Mitchell
Dan Palfrey
Luca Pisterzi (ex-Officio)
Mina Tadrous
Vidhi Thakkar

Message from the President

Welcome to the 2020 Canadian Association for Population Therapeutics (CAPT) / Association Canadienne pour la Thérapeutique des Populations (ACTP) annual conference. COVID-19 has had a huge impact on our lives: altering how we work, interact with one another, and carry on with our daily routines. CAPT-ACTP has also adapted, offering its program virtually this year and most importantly, **free to all attendees**. This allows us to engage a broader audience that shares our mission to advance population-based research of therapeutic interventions.

Our theme this year is “**Managing risk to improve health outcomes: how to move population health forward in an era of uncertainty**”, which is timely, given the challenges faced and the unknowns related to the global pandemic.

I would like to thank our sponsors for their generous contributions that have enabled us to host this event, our presenters who have compiled engaging presentations, and our attendees for joining us. I would also like to thank the CAPT-ACTP Board and the various committees that have worked diligently throughout the year to plan this conference.

A special thank you to CAPT-ACTP’s Scientific Program Committee, who has worked hard to create a meaningful and relevant agenda, our Local Organizing Committee, which has worked behind the scenes to ensure this conference is a success, and the Partnership Committee, who has worked closely with our sponsors to incorporate their vision. Without the work of these three committees, this conference would not be possible.

Undoubtedly, this year’s conference experience will be different but by no means less enriching. In previous years, we would convene Monday evening to mingle with colleagues and review posters, instead this will be now be held virtually, with each poster made available on our website. We have also summarized the content of our Annual General Meeting, which will be sent via email to all members.

Please take the time to complete our post-conference evaluation, your input and ideas are highly valued by the 2020 CAPT-ACTP team.

And, make sure to follow us on Twitter at @CAPT_ACTP and please tweet your conference observations over the next two days with the hashtag #CAPT_ACTP2020.

Luca F. Pisterzi, PhD
CAPT-ACTP President

Conference Overview

Welcome to the 2020 CAPT-ACTP conference! The theme of the conference, *“Managing risk to improve health outcomes: how to move population health forward in an era of uncertainty”* is ever so appropriate this year, given how COVID-19 has impacted all aspects of our lives. It has also brought forward new challenges to the scientific community around research, policy and practice, and we are collectively learning to navigate through and answer some of the questions raised.

While our conference looks a bit different this year, the Scientific Program Committee has been working hard to ensure that we are still able to deliver content that is valuable to our audience. Through our diverse program this year, we have continued to focus on sharing CAPT-ACTP’s Vision of linking population-based therapeutic research, policy and practice to lead to improved health outcomes. We are pleased to present a number of panel discussions, which bring together the diverse perspectives and expertise of our speakers. This year, we are proud to be able to showcase the exciting research achievements of our members as oral presentations in not one, but three breakout rooms, and present a virtual gallery of poster presentations, which will be available on our website.

CAPT-ACTP is proud to be able to share the scientific knowledge and valuable research of our members with a broader audience, by offering complimentary registration to this year’s virtual conference. We also encourage audience engagement by participating in the sessions via our virtual Q&A.

The Scientific Program Committee would like to thank our partners who have made the presentation of this year’s conference possible, and have continued to support CAPT-ACTP despite adapting to changes this year. We hope that it won’t be long before we are able to safely enjoy the company of each other in person at the conference, and we look forward to those days in anticipation. Until then, we look forward to meeting you virtually. We hope that you enjoy the conference!

Shazia Hassan
CAPT-ACTP Scientific Program Committee Chair

Monday, October 26, 2020

11:00AM – 11:15AM Welcome to Day 1

Speaker: Luca Pisterzi, CAPT-ACTP President

11:15AM – 12:00PM Opening: CADTH/CanREValue updates on the progress of RWE in Canada

Moderator: Mina Tadrous, Women's College Hospital

Speakers: Dr. Kelvin Chan (Sunnybrook Odette Cancer Centre),
Nicole Mittmann, CADTH

Session Overview: CanREValue has been established to identify knowledge gaps in evidence generation, and has brought together various stakeholders to develop a framework for the generation and use of Real World Evidence (RWE) for cancer drug funding decisions in Canada. As well, since the establishment of the multidisciplinary RWE Core Action Team at CADTH, the team has been working on sharing initiatives, supporting the development of a pan-Canadian approach to the use of RWE and identifying where RWE can add value to regulatory and reimbursement decision-makers. CanREValue and CADTH will present an update on their activities and provide some insights into what the future might hold.

12:00PM – 1:30PM Session 1: Making value-based agreements a reality in Canada through Real-World Evidence

Sponsored by:  AstraZeneca

Moderator: Judith Glennie, J.L. Glennie Consulting Inc.

Speakers: Winson Cheung, University of Calgary, Oncology Outcomes (O2)
Barry Stein, Colorectal Cancer Canada
Parneet Cheema, William Osler Health System
Sylvie Bouchard, INESSS

Session Overview: There is much discussion about the potential for RWE generation to address clinical and/or economic uncertainties in Canadian health technology assessment (HTA) recommendations. Despite this, there is no consensus on how to operationalize RWE in reimbursement decision making and no agreed-to method for data collection to leverage RWE as part of value-based agreements (VBA). As payer, academic, clinician, and patient group perspectives will be critical in making real-world evidence, this panel will explore the desire among stakeholders to overcome these barriers in Canada, as has already been accomplished in other countries. Fostering trust among different stakeholders is of paramount importance and can be a realistic goal if all parties commit to transparency and shared goals of delivering innovation and improving patient outcomes.

1:30PM – 1:40PM Break

1:40PM – 3:10PM Session 2: Adoption of Novel therapeutics in the Canadian healthcare system: learnings from CAR T cell therapy

Sponsored by:  **Biogen**

Moderator: Farah Jivraj, Biogen Canada

Speakers: Sabrina Hanna, The Cancer Collaborative

Brent Fraser, CADTH

Scott Gavura, Cancer Care Ontario

Ralph Meyer, Hamilton Health Sciences Centre

Sophie Rochon, Novartis

Session Overview: The continued advancement of cell and gene therapies promises to transform the treatment of disease and delivery of healthcare for patients, while also fundamentally disrupting and straining Canada's traditional HTA and drug reimbursement processes. This panel will explore recent CADTH process updates related to evaluating cell and gene therapies, as well as Canadian case studies & considerations for how to tackle this exciting challenge in Canadian healthcare going forward.

3:10PM – 3:15PM Day 1 Summary

Speaker: Luca Pisterzi, CAPT-ACTP President

Presentation of the Kris Schindel Award

Remarks from recipient

Tuesday, October 27, 2020

11:00AM – 11:15AM Welcome to Day 2

Speaker: Luca Pisterzi, CAPT-ACTP President

11:15AM – 12:45PM Session 3: Modern methods of generating Real World Evidence to demonstrate value

Sponsored by:  IQVIA™

Moderator: Brad Millson, IQVIA Canada

Speakers: Francois Peloquin, Pfizer
Farah Husein, Takeda
Charles Victor, IC/ES & Nicole Yada, IC/ES
Laurie Lambert, CADTH

Session Overview: This session will showcase how the collection of Real World Evidence (RWE) in Canada is rapidly evolving. We will examine innovative approaches to generating, analyzing and interpreting RWE and how that can be used to support value decisions in the health care system. Panelists will discuss new developments in RWE, views of the importance of RWE and its application to subjects such as value based agreements, healthcare decision making and addressing unmet needs.

12:45PM – 01:00PM Break

01:00PM – 2:00PM Session 4: Oral Presentations

Sponsored by:  **GILEAD**
Advancing Therapeutics.
Improving Lives.

J.L. Glennie Consulting Inc.



Breakout Room 1: Policy and Reimbursement

Moderator: Adam Haynes

Impact of Patented Medicine Prices Review Board new reference countries on drug prices in Canada: A comparison of current and anticipated list prices for top drugs in the country

Presenter: Chloé Langevin (student)

A retrospective view on plan sustainability in 2019 from a large Canadian private payer

Presenter: Anjila Arora & Sarah Nguyen

Reimbursement Recommendations of Conditionally-Approved Cancer Drugs in Canada

Presenter: Emily Arthur (student)

Analysis of biosimilars private claims data in Canada

Presenter: Dylan Lamb-Palmer

Breakout Room 2: Real-world Studies

Moderator: Jon Feairs

Using real world data to determine health system costs of Canadians diagnosed with chronic lymphocytic leukemia

Presenter: Soo Jin Seung

Impact of the COVID-19 pandemic on chronic pain management: A web-based pan-Canadian study

Presenter: Anais Lacasse

Sociodemographic, Disease, and Medication Profile of RA Patients under 65 years Compared with 65 Years or Older at Registry Enrollment: Data from A Rheumatoid Arthritis Cohort

Presenter: Mohammad Movahedi

Comparing Academic and Community Practices in the Management of Rheumatoid Arthritis: Data from the OBRI Registry

Presenter: Elliot Hepworth (student) & Reza Mirza

Characteristics of a population exposed to a disease-modifying drug for multiple sclerosis in the real-world setting (1996-2017)

Presenter: Huah Shin Ng (student)

Breakout Room 3: Chronic Diseases & Care

Moderator: Paul Henricks

Evaluation of the long-term cost-effectiveness of the Dexcom G6 continuous glucose monitor versus self-monitoring of blood glucose in people with type 1 diabetes in Canada

Presenter: Stéphane Roze

Non-Steroidal Anti-Inflammatory Drug Use Does Not Adhere To Prescribing Guidelines for Older Men or Women with Dementia

Presenter: Shanna Trenaman (student)

Examining self-monitoring of blood glucose in the Nova Scotia public pharmacare program

Presenter: Troy Hillier (student)

Persistence in Rheumatoid Arthritis Patients on Biosimilar and Bio-Originator Etanercept: A Pooled Analysis of Pan-Canadian Cohorts

Presenter: Cristiano Moura

Mental health in the workplace: The economic costs of productivity losses due to presenteeism and sickness absence in Canadian workers having psychological distress

Presenter: Mahée Gilbert-Ouimet

2:00PM – 2:15PM Break

2:15PM – 3:45PM Session 5: Pharmacoeconomic Analysis and Outcome-based agreements: What does it mean for Canadian Private Payers?

Sponsored by:  **Sun Life**

Moderator: Julie Blouin, Sun Life
Speakers: Daria O'Reilly, TELUS Health
Ned Pojskic, Greenshield
Sumeet Singh, Eversana
Lou Garrison, University of Washington

Session Overview: With the growing number of high-cost drugs, many Canadian private payers include cost-effectiveness as part of their value assessment for new drugs or new indications. In Canada's mixed healthcare system, while the economic perspective of a publicly funded health care payer is well established, the perspective of private payers is not. It's common to have real-world evidence and outcome-based agreements discussed from the lens of public payers, but what about private payers? Is the private sector ready for these types of agreements? What can we learn from other countries that have factored in private payers like the U.S.?

In the first part of this panel session, speakers will discuss the value of economic evaluations for Canadian private payers, and which costs, outcomes, time horizon and cost-effectiveness thresholds are relevant for an analysis in adopting a Canadian private payer's perspective. In the second part of the panel, speakers will discuss the gaps and key elements to consider when implementing outcome-based agreements that would involve private payers.

3:45PM – 4:00PM Closing Remarks – awards presentations

Speaker: Shazia Hassan, CAPT-ACTP President 2021

Abstract Booklet and Posters can be found at <https://www.capt-actp.ca/conference/>

For any inquiries, please contact Ms. Peggy Kee (peggy.kee@sunnybrook.ca), or visit the CAPT-ACTP website at: (www.capt-actp.ca).

2020 Conference Partners

LEVEL 1

AstraZeneca Canada Inc.
Biogen
IQVIA
SunLife

LEVEL 2

Gilead Sciences Canada Inc.
J.L. Glennie Consulting Inc.

LEVEL 3

Astellas
Hoffmann-La Roche
HOPE Research Centre
IHE Institute of Health Economics
Leo Pharma
PDCI
Takeda

We gratefully acknowledge sponsorship of the 2020 CAPT-ACTP conference by the following donors:

LEVEL 1 PARTNERS



LEVEL 2 PARTNERS



J.L. Glennie Consulting Inc.



LEVEL 3 PARTNERS

